STOCK TITAN

Praxis (PRAX) CEO acquires 126 ESPP shares as compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Praxis Precision Medicines CEO Marcio Souza reported a routine compensation-related stock acquisition. On May 14, 2026, he acquired 126 shares of Common Stock at $167.943 per share under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this grant, he directly owns 77,016 shares of Praxis common stock and has an additional 2,600 shares held indirectly through his spouse.

Positive

  • None.

Negative

  • None.
Insider Souza Marcio
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Stock 126 $167.943 $21K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 77,016 shares (Direct, null); Common Stock — 2,600 shares (Indirect, Held by spouse)
Footnotes (1)
  1. [object Object]
ESPP shares acquired 126 shares Common Stock granted under Employee Stock Purchase Plan on May 14, 2026
ESPP share price $167.943 per share Price for 126 ESPP shares acquired by CEO
Direct holdings after transaction 77,016 shares Praxis common stock directly owned by CEO after ESPP acquisition
Indirect holdings 2,600 shares Praxis common stock held indirectly by spouse as a reported holding
Employee Stock Purchase Plan financial
"These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3(d) regulatory
"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
Rule 16b-3(c) regulatory
"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
indirect ownership financial
"total_shares_following_transaction: 2600.0000, direct_or_indirect: I, nature_of_ownership: Held by spouse"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Souza Marcio

(Last)(First)(Middle)
C/O PRAXIS PRECISION MEDICINES, INC.
99 HIGH STREET, 30TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026A(1)126A$167.94377,016D
Common Stock2,600IHeld by spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Remarks:
/s/ Alex Nemiroff, as Attorney-in-Fact05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Praxis (PRAX) CEO Marcio Souza report?

Praxis CEO Marcio Souza reported acquiring 126 shares of common stock. The shares were obtained through the Employee Stock Purchase Plan as a compensation-related award, rather than an open-market purchase, and are disclosed as exempt under SEC Rule 16b-3 provisions.

How many Praxis (PRAX) shares does the CEO hold after this Form 4?

After this transaction, Marcio Souza holds 77,016 Praxis common shares directly. The filing also lists 2,600 additional shares held indirectly by his spouse, giving investors a clearer picture of his total reported equity exposure to Praxis Precision Medicines.

Was the Praxis (PRAX) CEO’s share acquisition an open-market buy?

No, the 126-share acquisition was made under the Praxis Precision Medicines Employee Stock Purchase Plan. The filing notes the transactions were exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a compensation-related plan purchase, not a discretionary market trade.

What price per share did the Praxis (PRAX) CEO pay under the ESPP?

The Form 4 reports a transaction price of $167.943 per share for the 126 acquired shares. This price is specific to the Employee Stock Purchase Plan transaction disclosed, and it helps quantify the value of this compensation-related equity award for the reporting period.

How are the Praxis (PRAX) shares held indirectly by the CEO reported?

The filing identifies 2,600 Praxis common shares as held indirectly, described as “Held by spouse.” This entry is characterized as a holding, not a new transaction, and provides transparency about equity beneficially associated with the CEO through a family relationship.